Go Pro
NASDAQ:XBIT

XBiotech Q4 2024 Earnings Report

XBiotech logo
$2.19 -0.01 (-0.45%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$2.19 0.00 (0.00%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XBiotech EPS Results

Actual EPS
-$0.34
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XBiotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

XBiotech Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

XBiotech Earnings Headlines

MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.tc pixel
XBiotech: Q4 Earnings Snapshot
See More XBiotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XBiotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XBiotech and other key companies, straight to your email.

About XBiotech

XBiotech (NASDAQ:XBIT) is a biotechnology company focused on developing therapies that target inflammation and other disease processes. The company’s technology platform is based on “True Human” monoclonal antibodies, which are derived from naturally occurring human antibodies rather than genetically engineered or animal-derived antibody sequences.

XBiotech’s research has included bermekimab, a fully human antibody designed to neutralize interleukin-1 alpha, an inflammatory protein associated with cancer, autoimmune conditions and other diseases. The company has evaluated bermekimab in clinical studies involving cancer and inflammatory disorders, while continuing to research additional antibody-based treatments and potential applications.

Founded in 2005 and headquartered in Austin, Texas, XBiotech has pursued the discovery, development and potential commercialization of biological therapies for patients in the United States and international markets. John Simard, the company’s founder, has served as its chairman and chief executive officer.

View XBiotech Profile